Professor Richard Scolyer on the need for more funding for brain cancer | 7.30

Key Concepts

• Brain Cancer Treatment: The discussion centers on novel approaches to treating aggressive brain tumors, particularly the use of immunotherapy.
• Immunotherapy: A treatment that stimulates the body's immune system to fight cancer.
• Neoadjuvant Therapy: Treatment administered before a primary treatment (like surgery) to improve its effectiveness.
• Melanoma vs. Brain Cancer Research: Contrasting the significant advancements in melanoma treatment with the relative stagnation in brain cancer research.
• Challenges in Brain Cancer Research: Identifying the inherent difficulties in studying brain tumors due to the brain's protected environment and the integral nature of brain cells.
• Funding and Coordination: Emphasizing the critical need for increased funding and collaborative efforts from government, private organizations, and philanthropists to advance brain cancer research.

Summary

Richard Scolio, a patient and researcher, shares his experience with aggressive brain cancer and his perspective on the challenges and future directions of brain cancer research. Despite a grim prognosis of 12-14 months median survival for his type of tumor, Scolio expresses happiness and gratitude for being able to function and engage in this conversation.

Current Treatment and Personal Experience

Scolio is actively undergoing treatment for his brain cancer. He highlights the aggressive nature of his tumor and the generally poor survival rates associated with it. He discusses a risky but potentially impactful approach he is undertaking, inspired by the pioneering work in melanoma treatment at the Melanoma Institute. This approach involves using immunotherapy, a treatment that enhances the immune system's ability to fight cancer.

A key aspect of Scolio's treatment is the administration of immunotherapy before surgery. This is a departure from traditional approaches and is based on the understanding that immunotherapy can be more effective when there is a larger tumor burden. While this strategy carries risks, including the potential for the tumor to grow more aggressively, Scolio felt it was a worthwhile endeavor, especially given the lack of significant progress in brain cancer survival rates for over two decades. He emphasizes that his experience as a single patient generates scientific data but does not prove efficacy; a proper clinical trial is necessary to validate this approach.

Challenges in Brain Cancer Research

Scolio addresses the stark contrast between the rapid advancements in melanoma treatment and the slow progress in brain cancer. He attributes this disparity to several factors:

• Inaccessibility of Tissue: The brain's location within the skull limits the ability to obtain large tissue samples for research.
• Integral Nature of Brain Cells: Unlike other organs, most cells in the brain are essential for its function. This makes it difficult to target cancer cells without affecting healthy brain tissue and its complex functions, such as multitasking and specialized regional capabilities.
• Tumor Location and Treatment Decisions: The specific location of a brain tumor, like Scolio's in the temporal lobe, necessitates careful consideration by clinicians to balance treatment effectiveness with the preservation of vital functions and quality of life.

Call for Action and Future Directions

Scolio passionately advocates for increased investment and coordinated efforts in brain cancer research. He points out that brain cancer is the most common cancer in individuals under 40, yet the research funding and progress do not reflect this reality.

He stresses the need for:

• Teamwork and Collaboration: Bringing together diverse skill sets and fostering collaboration among researchers, clinicians, and institutions is crucial for a greater impact.
• Increased Funding: He calls for significant contributions from state and federal governments, as well as private organizations and philanthropists. He believes that government funding should be a primary driver.
• Community Engagement: He observes that the public tends to support causes when they understand the issues and the potential for impact.

Scolio's motivation for speaking out, even as a patient, stems from his prior experience in research and his understanding of what needs to be done. He believes that difficult but achievable research can be better organized and funded to make a tangible difference in brain cancer outcomes. He specifically urges federal and state governments to prioritize and push forward this agenda.

Conclusion

Richard Scolio's personal journey with brain cancer underscores the urgent need for a paradigm shift in how brain cancer is researched and treated. His willingness to embrace novel, albeit risky, therapeutic strategies and his articulate advocacy for increased funding and collaborative research highlight the critical gap in progress compared to other cancers. The core message is a powerful call to action for all stakeholders to unite and invest in brain cancer research to improve outcomes for a vulnerable patient population.